Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect.

Institute of Cell Biology, Eidgenössische Technische Hochschule (ETH) Zürich, Zürich, Switzerland.
The American Journal of Human Genetics (Impact Factor: 10.99). 02/2011; 88(2):162-72. DOI: 10.1016/j.ajhg.2011.01.008
Source: PubMed

ABSTRACT Neuromuscular junctions (NMJs) are synapses that transmit impulses from motor neurons to skeletal muscle fibers leading to muscle contraction. Study of hereditary disorders of neuromuscular transmission, termed congenital myasthenic syndromes (CMS), has helped elucidate fundamental processes influencing development and function of the nerve-muscle synapse. Using genetic linkage, we find 18 different biallelic mutations in the gene encoding glutamine-fructose-6-phosphate transaminase 1 (GFPT1) in 13 unrelated families with an autosomal recessive CMS. Consistent with these data, downregulation of the GFPT1 ortholog gfpt1 in zebrafish embryos altered muscle fiber morphology and impaired neuromuscular junction development. GFPT1 is the key enzyme of the hexosamine pathway yielding the amino sugar UDP-N-acetylglucosamine, an essential substrate for protein glycosylation. Our findings provide further impetus to study the glycobiology of NMJ and synapses in general.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Congenital myasthenic syndromes (CMSs) are a group of heterogeneous inherited disorders caused by mutations in genes affecting the function and structure of the neuromuscular junction. This review updates the reader on established and novel subtypes of congenital myasthenia, and the treatment strategies for these increasingly heterogeneous disorders. The discovery of mutations associated with the N-glycosylation pathway and in the family of serine peptidases has shown that causative genes encoding ubiquitously expressed molecules can produce defects at the human neuromuscular junction. By contrast, mutations in lipoprotein-like receptor 4 (LRP4), a long-time candidate gene for congenital myasthenia, and a novel phenotype of myasthenia with distal weakness and atrophy due to mutations in AGRN have now been described. In addition, a pathogenic splicing mutation in a nonfunctional exon of CHRNA1 has been reported emphasizing the importance of analysing nonfunctional exons in genetic analysis. The benefit of salbutamol and ephedrine alone or combined with pyridostigmine or 3,4-DAP is increasingly being reported for particular subtypes of CMS.
    Journal of Neurology 10/2014; 261(11). DOI:10.1007/s00415-014-7520-7 · 3.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tubular aggregate myopathy (TAM) is a hereditary muscle disorder that is pathologically characterized by the presence of tubular aggregates. The responsible genes have not been clarified for many individuals affected by TAM. In order to identify the genetic cause of TAM, we performed whole exome sequencing in genomic DNA from 2 families affected by dominant TAM with hypocalcemia. We identified one common variant in both families, heterozygous missense mutation, c.292G>A (Gly98Ser) in ORAI1. We also found an additional heterozygous missense mutation, c.412C>T (p.Leu138Phe) in ORAI1, in the third TAM family by Sanger sequencing. The mutations were not listed in dbSNP137, 1000genomes, or Human Genetic Variation Database collecting Japanese genetic variations. Orai1 is a cell-surface transmembrane protein which acts as a store-operated Ca2+ channel, is highly expressed in the skeletal muscles. The store-operated Ca2+ channel is activated by diminished luminal Ca2+ levels in the sarcoplasmic reticulum via the activation of stromal interaction molecule 1 (STIM1) sensing of Ca2+ depletion. We demonstrated that skeletal myotubes from an affected individual and HEK293 cells expressing mutated Orai1 proteins displayed spontaneous extracellular Ca2+ entry into cells independent of STIM1 activation. Our results indicated that calcium entry into myofibers via store-operated Ca2+ channels were constitutively activated by dominant mutations in ORAI1 that cause altered Ca2+ homeostasis, resulting in tubular aggregate myopathy with hypocalcemia. Recently, dominant mutations in STIM1 have been identified to cause tubular aggregate myopathy. Together, these results strongly suggest that the constitutive extracellular Ca2+ entry caused by a mutation in either the STIM1 or ORAI1 is associated with a certain type of tubular aggregate myopathy.
    Neuromuscular Disorders 10/2014; 24(s 9–10):792. DOI:10.1093/hmg/ddu477 · 3.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neuromuscular disorders are a clinically, pathologically, and genetically heterogeneous group. Even for the experienced clinician, an accurate diagnosis is often challenging due to the complexity of these disorders. Here, we investigated the utility of next generation sequencing (NGS) in early diagnostic algorithms to improve the diagnosis for patients currently lacking precise molecular characterisation, particularly for hereditary myopathies. 43 patients presenting with early onset neuromuscular disorders from unknown genetic origin were tested by NGS for 579 nuclear genes associated with myopathy. In 21 of the 43 patients, we identified the definite genetic causes (48.8%). Additionally, likely pathogenic variants were identified in seven cases and variants of uncertain significance (VUS) were suspected in four cases. In total, 19 novel and 15 known pathogenic variants in 17 genes were identified in 32 patients. Collagen VI related myopathy was the most prevalent type in our cohort. The utility of NGS was highlighted in three cases with congenital myasthenia syndrome, as early diagnosis is important for effective treatment. A targeted NGS can offer cost effective, safe and fairly rapid turnaround time, which can improve quality of care for patients with early onset myopathies and muscular dystrophies; in particular, collagen VI related myopathy and congenital myasthenia syndromes. Nevertheless, a substantial number of patients remained without molecular diagnosis in our cohort. This may be due to the intrinsic limitation of detection for some types of mutations by NGS or to the fact that other causative genes for neuromuscular disorders are yet to be identified. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to
    Journal of Medical Genetics 01/2015; 52(3). DOI:10.1136/jmedgenet-2014-102819 · 5.64 Impact Factor

Full-text (2 Sources)

Available from
Jun 10, 2014

Marina Dusl